Clovertex’s September 2025 Target of the Month is LGR5, in light of Genmab’s announcement that it wi...
Clovertex’s August 2025 Target of the Month is MC4R (melanocortin‑4 receptor). MC4R is a GPCR that p...
Clovertex’s June Target of the Month is KIT, highlighted by Sanofi’s acquisition of Blueprint Medici...
Clovertex’s May Target of the Month is B-Raf, a serine/threonine kinase that plays a central role in...
Clovertex’s April 2025 Target of the Month is the neonatal Fc receptor (FcRn), following the U.S. FD...
Clovertex’s March Target of the Month is GSPT1, a translation termination factor that plays a vital ...
Clovertex's February Target of the Month is the farnesoid X receptor (FXR), a nuclear receptor that ...
Clovertex’s January Target of the Month is Dopamine D2 Receptor (D2R), highlighted by Johnson & John...
Clovertex’s Target of the Year 2024 is the Gastric Inhibitory Polypeptide Receptor (GIPR), which has...
Clovertex’s December Target of the Month is the Dystrophin-Glycoprotein Complex (DGC), inspired by a...